Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.
Applicants must adhere to new timelines: submit a rapporteurs' allocation request 9 months prior to the intended MAA submission date, and submit their Letter of Intent at least 2 months before the MAA submission.
Stakeholders must express interest in the pilot by submitting an application form prior to the full submission of data, with the pilot set to run through 2027.
Manufacturers must now incorporate expert panel feedback into their conformity assessment processes, ensuring timely integration of provided expert advice into their evaluation and regulatory submissions.
Update local protocols to ensure parenteral nutrition is administered with filters in compliance with the new requirements.
Healthcare facilities must initiate the removal process for affected lots, isolate impacted products, and communicate the recall information to all relevant healthcare professionals. Compliance with the outlined return process is mandatory.
Pharmacies within healthcare establishments must review the safety information and adhere to the guidance issued by ANSM regarding the usage of the device.
